A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Clinical trial NCT04281472 · COMPLETED
Trial details
- NCT number
- NCT04281472
- Sponsor
- argenx
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-15
- Primary completion
- 2023-05-11
- Enrollment
- 322
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.